Share >  
Share
Share on Tumblr

Pharmasianews

News »

   latest by relevance
Cipla's price cut is strategic move: Expert
May 04, 2012 at 13:01 | Source: CNBC-TV18
Cipla's move to slash price of its cancer drug by almost 75% is a strong one, this is not only a humanitarian move, but is a strategic play as well, Vikas Dandekar of Pharmasianews.com told CNBC-TV18.
Ranbaxy to have 30% mkt share for Lipitor: PharmAsiaNews
Dec 01, 2011 at 08:56 | Source: CNBC-TV18
Vikas Dandekar of PharmAsiaNews.com tells CNBC-TV18 that the US FDA approval for Lipitor is definitely going to be a big positive for Ranbaxy.
Piramal-Vodafone fair deal but core biz worries exist
Aug 10, 2011 at 22:45 | Source: CNBC-TV18
In an interview to CNBC-TV18, Vikas Dandekar, India bureau chief of Pharmasianews, says the Pirmal-Vodafone deal is a smart move but the question remains on what happens to the core business. However, he says, over a longer period of time there will be some value accretion.
Ranbaxy launches Generic Aricept in US market; stk gains
Nov 29, 2010 at 09:27 | Source: Moneycontrol.com
Ranbaxy Laboratories has launched Generic Aricept in US market, quoting PharmAsiaNews, reports CNBC-TV18. It touched an intraday high of Rs 572.95 and an intraday low of Rs 561. At 09:24 hrs the share was quoting at Rs 567.95, up Rs 23.10, or 4.24%.
Pfizer sees good value in deal with Biocon: Pharmasianews
Oct 18, 2010 at 19:14 | Source: CNBC-TV18
Biocon and Pfizer have entered into a global commercialisation agreement. Pfizer will make an upfront payment of USD 200 million for the licensing deal for Biocons biosimilar insulin portfolio diabetics treatment. In an interview with CNBC-TV18, Vikas Dandekar of pharmasianews.com gave his perspective on the deal.
Pharma M&A: Should govt fret over foreign takeovers?
Aug 25, 2010 at 22:25 | Source: CNBC-TV18
Pharmaceutical major Ranbaxy may offer to pay a one-time penalty to the US Food and Drug Administration (FDA), learns CNBC-TV18 quoting sources. In an interview with CNBC-TV18's Executive Editor Shereen Bhan and News Editor Harsha Subramaniam, Vikas Dandekar of Pharmasianews.com gave his perspective on the issue.

Videos »
Cipla's price cut is strategic move: Expert
Ranbaxy to have 30% mkt share for Lipitor: PharmAsiaNews
Piramal-Vodafone fair deal but core biz worries exist
Pfizer sees good value in deal with Biocon: Pharmasianews
Pharma M&A: Should govt fret over foreign takeovers?
more »

Photos »

  /  

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window